Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

MicroRNA-300 inhibits the metastasis of prostate cancer through the regulation of TRIM63

Dechen Ma, Yin Chen, Qingqiu Ge, Yasheng Huang

Department of Urology Surgery, Hangzhou Hospital of Traditional Chinese Medicine, Hangzhou, China;

For correspondence:-  Yasheng Huang   Email: kk2158@163.com   Tel:+8613018961068

Accepted: 25 February 2022        Published: 31 March 2022

Citation: Ma D, Chen Y, Ge Q, Huang Y. MicroRNA-300 inhibits the metastasis of prostate cancer through the regulation of TRIM63. Trop J Pharm Res 2022; 21(3):479-484 doi: 10.4314/tjpr.v21i3.4

© 2022 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the role of microRNA-300 in the tumorigenesis of prostate cancer (PCa), and the relationship between microRNA-300 level and clinical data of PCa patients.
Methods: MicroRNA-300 levels in 63 matched PCa and adjacent tissues were determined via quantitative real-time polymerase chain reaction (qRT-PCR). The relationship between microRNA-300 level and the clinical profile of PCa patients was assessed. PCa cell phenotypes influenced by microRNA-300 were evaluated by a series of functional experiments, including CCK-8, colony formation, Transwell and wound healing assays. The role of microRNA-300/TRIM63 axis in the development of PCa was also examined.
Results: MicroRNA-300 was more lowly expressed in PCa tissues than in adjacent normal tissues. PCa patients expressing lower levels of microRNA-300 had a higher Gleason score, higher rates of lymphatic metastasis and distant metastasis, and lower survival. Overexpression of microRNA-300 suppressed its proliferative and metastatic potential. Dual-luciferase reporter assay data confirmed that microRNA-300 specifically binds Tripartite Motif-containing Protein 63 (TRIM63). TRIM63 level was downregulated in PCa cells overexpressing microRNA-300. Moreover, overexpression of TRIM63 abolished the role of microRNA-300 in influencing PCa cell phenotypes.
Conclusion: MicroRNA-300 is downregulated in PCa. Its level is related to Gleason score, lymphatic metastasis, distant metastasis and poor prognosis of PCa patients. MicroRNA-300 stimulates proliferative and metastatic abilities in PCa cells by targeting TRIM63. This study may provide new targets for the development of new therapeutics for of PCa as well as its diagnosis.

Keywords: MicroRNA-300, TRIM63, Prostate cancer, Gleason score, Lymphatic metastasis, Malignant progression

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates